Compare Becton Dickinson and Co (BDX) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.99. The key difference: Becton Dickinson and Co pays a 2.79% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| BDX | MSTU | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.39 | $106.80 |
52-Week Low | $135.49 | $1.46 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
MSTU (T-REX 2X Long MSTR Daily Target ETF) trades at $1.78, down 5.07% today amid significant bearish technical signals. The leveraged ETF tracking MicroStrategy has experienced extreme volatility, with news reports indicating a 95% decline over the past year. Technical indicators show overwhelming bearish momentum with moving averages unanimously negative, while fundamental data remains unavailable for this specialized leveraged product.
The outlook remains highly speculative given the ETF's leveraged structure and dependence on MicroStrategy's Bitcoin-heavy strategy. Investment opportunity exists only for sophisticated traders comfortable with extreme volatility, while risks include daily rebalancing decay, concentration in a single stock, and amplified losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
